Publicación:
Mujer con diagnóstico de novo de espectro de neuromielitis óptica con anticuerpos para AQP4 positivo. Un Reporte de Caso

dc.contributor.authorRivera Rojas, Neiby Johanaspa
dc.contributor.authorNassar Tobón, Andrea Catalinaspa
dc.contributor.authorCaballero Amórtegui, Laura Angélicaspa
dc.date.accessioned2021-08-18T00:00:00Z
dc.date.accessioned2025-08-05T14:25:21Z
dc.date.available2021-08-18T00:00:00Z
dc.date.available2025-08-05T14:25:21Z
dc.date.issued2021-08-18
dc.description.abstractIntroducción: Presentamos el caso de una paciente de 55 años de edad, con antecedente de hipertensión arterial, quien presentó un cuadro de deterioro visual bilateral de 2 meses de evolución, con posterior presencia de un síndrome motor y sensitivo del hemicuerpo derecho asociado a compromiso de tórax y abdomen; las imágenes de resonancia magnética (RM) de cerebro, orbitas, columna cervical y torácica simple y con medio de contraste mostraron una neuritis óptica bilateral severa, asociado a mielopatía cervical longitudinalmente extensa de carácter inflamatorio, hallazgos sugestivos de un espectro de neuromielitis óptica (NMO), por lo que se llevó a toma de punción lumbar que mostró un líquido cefalorraquideo (LCR) con pleocitosis neutrofílica, AQP4 positiva, glucosa y proteínas normales. Recibió manejo con corticoides a altas dosis asociado a plasmaféresis con mejoría parcial de los síntomas; posteriormente se dio de alta, para inicio de manejo inmunomodulador con Rituximab, de forma ambulatoria.      Objetivo: Describir un caso y las características clínicas generadas en una paciente con neuromielitis óptica, su diagnóstico, tratamiento, evolución y pronóstico. Método: Se realizó una revisión de la historia clínica y extracción de datos previa firma de consentimiento informado, posteriormente se hizo una búsqueda de artículos de revisión   bibliográfica en PubMed, SCIELO, ProQuest, usando descriptores de Ciencias de la Salud (DeCs) y términos MeSH: reportes de caso, publicaciones y revisiones. Se usaron artículos comprendidos entre 2006 al 2018. Resultados: Se documentó la presentación clínica, el diagnóstico, evolución y tratamiento de acuerdo con el manejo dado. Discusión: Al enfrentarnos a un cuadro de una paciente con neuromielitis óptica, podemos encontrar diferentes espectros clínicos, evolución y respuestas al tratamiento.spa
dc.description.abstractIntroduction: We present the case of a 55-year-old patient, with a history of arterial hypertension, who presented a 2-month history of bilateral visual impairment, with subsequent presence of a motor and sensory syndrome of the right hemibody associated with chest involvement and abdomen; Magnetic resonance imaging (MRI) of the brain, orbits, cervical and thoracic spine simple and with contrast medium showed severe bilateral optic neuritis, associated with longitudinally extensive cervical myelopathy of an inflammatory nature, findings suggestive of a spectrum of neuromyelitis optica (NMO), for which a lumbar puncture was taken that showed cerebrospinal fluid (CSF) with neutrophilic pleocytosis, positive AQP4, glucose and normal proteins. He received management with high-dose corticosteroids associated with plasmapheresis with partial improvement of symptoms; Later, he was discharged to start immunomodulatory management with Rituximab, on an outpatient basis. Objective: Describe a case and the clinical characteristics generated in a patient with optic neuromyelitis, its diagnosis, treatment, evolution and prognosis. Method: A review of the clinical history and data extraction was carried out after signing the informed consent, then a search was made for bibliographic review articles in PubMed, SCIELO, ProQuest, using Health Sciences descriptors (DeCs) and MeSH terms: Case reports, publishing, reviews. Articles from 2006 to 2018 were used. Results: The clinical presentation, diagnosis, evolution and treatment were documented according to the management given. Discussion: When faced with a picture of a patient with optic neuromyelitis, we can find different clinical spectra, evolution and response to variable treatment.  eng
dc.format.mimetypeapplication/pdfspa
dc.identifier.doi10.26752/cuarzo.v27.n1.521
dc.identifier.eissn2500-7181
dc.identifier.issn0121-2133
dc.identifier.urihttps://repositorio.juanncorpas.edu.co/handle/001/426
dc.identifier.urlhttps://doi.org/10.26752/cuarzo.v27.n1.521
dc.language.isospaspa
dc.publisherFundación Universitaria Juan N. Corpasspa
dc.relation.bitstreamhttps://revistas.juanncorpas.edu.co/index.php/cuarzo/article/download/521/461
dc.relation.citationendpage44
dc.relation.citationissue1spa
dc.relation.citationstartpage35
dc.relation.citationvolume27spa
dc.relation.ispartofjournalRevista Cuarzospa
dc.relation.referencesJarius S, Wildemann B. An early case of neuromyelitis optica: on a forgotten report by Jacob Lockhart Clarke, FRS. Mult. Scler. 2011; 17(11):1384-1386.spa
dc.relation.referencesDevic C. Myelite subaigue compliquee de nevrite optique. Bull Med. 1894; 35:18-30.spa
dc.relation.referencesJarius S, Wildemann B. The history of neuromyelitis optica. J Neuroinflammation. 2013; 10:8.spa
dc.relation.referencesYan Wu, Lianmei Zhong, Jia Geng. Neuromyelitis optica spectrum disorder: Pathogenesis, treatment, and experimental models. Mult Scler Relat Disord. 2019; 27:412-418.spa
dc.relation.referencesWingerchuk D, Banwell B, Bennett J, Cabre P, Carroll W, Chitnis T, et al., International consensus diagnostic criteria for neuromyelitis optica spectrum disorders. Neurology. 2015; 14;85(2):177-89.spa
dc.relation.referencesLevin M, Bennett J, Verkman A, Optic neuritis in neuromyelitis optica. Prog. Retin Eye Res. 2013; 36: 159–171.spa
dc.relation.referencesJarius S, Wildemann B, Paul F, Neuromyelitis optica: clinical features, immunopathogenesis and treatment. Clin. Exp. Immunol. 2014; 176(2): 149–164.spa
dc.relation.referencesWingerchuk D, Lennon V, Lucchinetti C, Pittock J, Weinshenker B. The spectrum of neuromyelitis optica. Lancet Neurol. 2007;6(9):805-815.spa
dc.relation.referencesTradtrantip L, Jin B, Yao X, Anderson M, Verkman A. Aquaporin-Targeted Therapeutics: State-of-the-Field. Adv Exp Med Biol. 2017; 969:239-250spa
dc.relation.referencesMajed M, Fryer J, McKeon A, Lennon V, Pittock S. Clinical utility of testing AQP4-IgG in CSF: Guidance for physicians. Neurol Neuroimmunol Neuroinflamm. 2016; 20;3(3).spa
dc.relation.referencesValentino P, Marnetto F, Granieri L, Capobianco M, Bertolotto A. Aquaporin-4 antibody titration in NMO patients treated with rituximab: A retrospective study. Neurol Neuroimmunol Neuroinflamm. 2016; 15;4(2): e317.spa
dc.relation.referencesKang H, Cao S, Chen T, Jiang Z, Liu Z, Li Z, Wei Y, Ai N, Xu Q, Lin Q, Wei S. The poor recovery of neuromyelitis optica spectrum disorder is associated with a lower level of CXCL12 in the human brain. J Neuroimmunol. 2015; 15 (289):56-61.spa
dc.relation.referencesTakano R, Misu T, Takahashi T, Sato S, Fujihara K, Itoyama Y. Astrocytic damage is far more severe than demyelination in NMO: a clinical CSF biomarker study. Neurology. 2010; 20;75(3)spa
dc.relation.referencesRosito S, Nicchia G, Palazzo C, Lia A, Buccoliero C, Pisani F, Svelto M, Trojano M, Frigeri A. Supramolecular aggregation of aquaporin-4 is different in muscle and brain: correlation with tissue susceptibility in neuromyelitis optica. J Cell Mol Med. 2018; 22(2):1236-1246.spa
dc.relation.referencesEtemadifar M, Salari M, Mirmosayyeb O, Serati M, Nikkhah R, Askari M, Fayyazi E. Efficacy and safety of rituximab in neuromyelitis optica: Review of evidence. J Res Med Sci. 2017; 16; 22:18spa
dc.relation.referencesChihara N, Aranami T, Sato W, Miyazaki Y, Miyake S, Okamoto T, Ogawa M, Toda T, Yamamura T. Interleukin 6 signaling promotes anti-aquaporin 4 autoantibody production from plasmablasts in neuromyelitis optica. Proc Natl Acad Sci U S A. 2011; 1;108(9):3701-6.spa
dc.relation.referencesGraber D, Levy M, Kerr D, Wade W. Neuromyelitis optica pathogenesis and aquaporin 4. J Neuroinflammation. 2008; 29;5:22.spa
dc.relation.referencesLi M, Yan Y. Experimental models of neuromyelitis optica: current status, challenges and future directions. Neurosci Bull. 2015; 31(6):735-44.spa
dc.relation.referencesLinhares UC, Schiavoni P, Barros P, Kasahara T, Teixeira B, Ferreira T, Alvarenga R, Hygino J, Vieira M, Bittencourt V, Andrade R, Andrade A, Bento C. The ex vivo production of IL-6 and IL-21 by CD4+ T cells is directly associated with neurological disability in neuromyelitis optica patients. J Clin Immunol. 2013; 33(1):179-89.spa
dc.relation.referencesAsgari N, Lillevang S, Skejoe H, Falah M, Stenager E, Kyvik K. A population-based study of neuromyelitis optica in Caucasians. Neurology. 2011; 3;76(18):1589-95.spa
dc.relation.referencesWingerchuk D. Neuromyelitis optica: new findings on pathogenesis. Int Rev Neurobiol 2007; 79:665–88.spa
dc.relation.referencesWingerchuk D, Hogancamp W, O'Brien P, Weinshenker B. The clinical course of neuromyelitis optica (Devic's syndrome). Neurology. 1999; 53(5):1107-14.spa
dc.relation.referencesSato D, Lana-Peixoto M, Fujihara K, de Seze J. Clinical spectrum and treatment of neuromyelitis optica spectrum disorders: evolution and current status. Brain Pathol. 2013; 23(6):647-60.spa
dc.relation.referencesJuryńczyk M, Craner M, Palace J. Overlapping CNS inflammatory diseases: differentiating features of NMO and MS. J Neurol Neurosurg Psychiatry. 2015 ;86(1):20-5.spa
dc.relation.referencesHage Jr R, Merle H, Jeannin S, Cabre P. Ocular oscillations in the neuromyelitis optica spectrum. J Neuroophthalmol 2011; 31:255–9.spa
dc.relation.referencesAltintas A, Karabudak R, Balci B, Terzi M, Soysal A, Saip S, et al. Neuromyelitis optica and neuromyelitis optica spectrum disorder patients in Turkish cohort: demographic, clinical, and laboratory features. Neurologist 2015;20:61–6.spa
dc.relation.referencesPittock S, Weinshenker B, Lucchinetti CF, Wingerchuk DM, Corboy J, Lennon V. Neuromyelitis optica brain lesions localized at sites of high aquaporin 4 expression. Arch Neurol. 2006;63(7):964-8.spa
dc.relation.referencesHuh S, Min J, Kim W, Kim S, Kim H, Kim B, Kim B, Lee K. The usefulness of brain MRI at onset in the differentiation of multiple sclerosis and seropositive neuromyelitis optica spectrum disorders. Mult Scler. 2014;20(6):695-704.spa
dc.relation.referencesJarius S, Ruprecht K, Wildemann B, Kuempfel T, RingelsteinM, Geis C, et al. ontrasting disease patterns in seropositive and seronegative neuromyelitis optica: A multicentre study of 175 patients. J Neuroinflammation. 2012;19;9:14spa
dc.relation.referencesKim H, Paul F, Lana-Peixoto M, Tenembaum S, Asgari N, Palace J, et al. MRI characteristics of neuromyelitis optica spectrum disorder: an international update. Neurology. 2015;84:1165–73.spa
dc.relation.referencesKhanna S, Sharma A, Huecker J, Gordon M, Naismith R, Van Stavern G. Magnetic resonance imaging of optic neuritis in patients with neuromyelitis optica versus multiple sclerosis. J Neuroophthalmol 2012;32:216–20.spa
dc.relation.referencesSahraian M, Radue E, Minagar A. Neuromyelitis optica: clinical manifestations and neuroimaging features. Neurol Clin 2013;31:139–52.spa
dc.relation.referencesBennett J, de Seze J, Lana-Peixoto M, Palace J, Waldman A, Schippling S, et al. Neuromyelitis optica and multiple sclerosis: seeing differences through optical coherence tomography. Mult Scler 2015;21:678–88.spa
dc.relation.referencesLange AP, Sadjadi R, Zhu F, Alkabie S, Costello F, Traboulsee A. Spectral-domain optical coherence tomography of retinal nerve fiber layer thickness in NMO patients. J Neuroophthalmol 2013;33:213–9.spa
dc.relation.referencesAbsoud M, Lim M, Chong W, De Goede C, Foster K, Gunny R, et al. Paediatric acquired demyelinating syndromes: incidence, clinical and magnetic resonance imaging features. Mult Scler 2013;19:76–86.spa
dc.relation.referencesTenembaum S, Chitnis T, Nakashima I, Collongues N, McKeon A, Levy M, et al. Neuromyelitis optica spectrum disorders in children and adolescents. Neurology 2016;87:S59–66.spa
dc.relation.referencesWingerchuk D, Weinshenker B. Neuromyelitis optica spectrum disorder diagnostic criteria: sensitivity and specificity are both important. Mult Scler 2017; 23:182–4.spa
dc.relation.referencesTakahashi T, Fujihara K, Nakashima I, Misu T, Miyazawa I, Nakamura M, et al. Antiaquaporin- 4 antibody is involved in the pathogenesis of NMO: a study on antibody titre. Brain 2007; 130:1235–43.spa
dc.relation.referencesJarius S, Aboul-Enein F, Waters P, Kuenz B, Hauser A, Berger T, et al. Antibody to aquaporin-4 in the long-termcourse of neuromyelitis optica. Brain 2008;131(3): 72–80.spa
dc.relation.referencesReindl M, Jarius S, Rostasy K, Berger T. Myelin oligodendrocyte glycoprotein antibodies: how clinically useful are they? Curr Opin Neurol 2017; 30:295–301.spa
dc.relation.referencesMelamed E, Levy M, Waters P, Sato D, Bennett J, John G, et al. Update on biomarkers in neuromyelitis optica. Neurol Neuroimmunol Neuroinflamm 2015;2:e134.spa
dc.relation.referencesFlanagan E, Hinson S, Lennon V, Fang B, Aksamit A, Morris P, et al. Glial fibrillary acidic protein immunoglobulin G as biomarker of autoimmune astrocytopathy: analysis of 102 patients. Ann Neurol 2017; 81:298–309.spa
dc.relation.referencesPetzold A, Plant G. Diagnosis and classification of autoimmune optic neuropathy. Autoimmun Rev 2014;13:539–45.spa
dc.relation.referencesKremer S, Renard F, Achard S, Lana-Peixoto M, Palace J, Asgari N, et al. Use of advanced magnetic resonance imaging techniques in neuromyelitis optica spectrum disorder. JAMA Neurol 2015;72:815–22.spa
dc.relation.referencesBruscolini A, Sacchetti M, La Cava M, Gharbiya M, Ralli M, Lambiase A, De Virgilio A, Greco A. Diagnosis and management of neuromyelitis optica spectrum disorders - An update. Autoimmun Rev. 2018;17(3):195-200.spa
dc.relation.referencesAbboud H, Petrak A, Mealy M, Sasidharan S, Siddique L, Levy M. Treatment of acute relapses in neuromyelitis optica: steroids alone versus steroids plus plasma exchange. Mult Scler 2016;22:185–92.spa
dc.relation.referencesBonnan M, Cabre P. Plasma exchange in severe attacks of neuromyelitis optica. Mult Scler Int 2012;787630.spa
dc.relation.referencesBiswas A, Mukherjee A. Therapy of NMO spectrum disorders. Ann Indian Acad Neurol 2015;18:S16–23.spa
dc.relation.referencesMealy M, Wingerchuk D, Palace J, Greenberg B, Levy M. Comparison of relapse and treatment failure rates among patients with neuromyelitis optica: multicenter study of treatment efficacy. JAMA Neurol 2014; 71:324–30.spa
dc.relation.referencesTorres J, Pruitt A, Balcer L, Galetta S, Markowitz C, Dahodwala N. Analysis of the treatment of neuromyelitis optica. J Neurol Sci. 2015;351:31–5.spa
dc.relation.referencesKasama T, Isozaki T, Takahashi R, Miwa Y. Clinical effects of tocilizumab on cytokines and immunological factors in patients with rheumatoid arthritis. Int Immunopharmacol. 2016;35:301–6.spa
dc.relation.referencesKieseier BC, Stuve O, Dehmel T, Goebels N, Leussink VI, Mausberg AK, et al. Disease amelioration with tocilizumab in a treatment-resistant patient with neuromyelitis optica: implication for cellular immune responses. JAMA Neurol. 2013;70(3):390spa
dc.relation.referencesPittock SJ, Lennon VA, McKeon A, Mandrekar J, Weinshenker BG, Lucchinetti CF, et al. Eculizumab in AQP4-IgG-positive relapsing neuromyelitis optica spectrum disorders: an open-label pilot study. Lancet Neurol. 2013;12:554–62.spa
dc.relation.referencesTradtrantip L, Zhang H, Saadoun S, Phuan P, Lam C, Papadopoulos M, et al. Antiaquaporin-4 monoclonal antibody blocker therapy for neuromyelitis optica. Ann Neurol 2012;71:314–22.spa
dc.relation.referencesVerkman A, Ratelade J, Rossi A, Zhang H, Tradtrantip L. Aquaporin-4: orthogonal array assembly, CNS functions, and role in neuromyelitis optica. Acta Pharmacol Sin. 2011;32:702–10spa
dc.relation.referencesIwata K, Doi A, Ohji G, Oka H, Oba Y, Takimoto K, et al. Effect of neutrophil elastase inhibitor (sivelestat sodium) in the treatment of acute lung injury (ALI) and acute respiratory distress syndrome (ARDS): a systematic review and meta-analysis. Intern Med. 2010;49:2423–32spa
dc.relation.referencesHerges K, de Jong B, Kolkowitz I, Dunn C, Mandelbaum G, Ko R, et al. Protective effect of an elastase inhibitor in a neuromyelitis optica-like disease driven by a peptide of myelin oligodendroglial glycoprotein. Mult Scler. 2012;18:398–408.spa
dc.relation.referencesSaadoun S, Waters P, MacDonald C, Bell BA, Vincent A, Verkman AS, et al. Neutrophil protease inhibition reduces neuromyelitis optica-immunoglobulin G-induced damage in mouse brain. Ann Neurol. 2012;71:323–33.spa
dc.relation.referencesZhang H, Verkman A. Eosinophil pathogenicity mechanisms and therapeutics in neuromyelitis optica. J Clin Invest. 2013;123:2306–16.spa
dc.relation.referencesSteinman L, Bar-Or A, Behne J, Benitez-Ribas D, Chin P, Clare-Salzler M, et al. Restoring immune tolerance in neuromyelitis optica: part I. Neurol Neuroimmunol Neuroinflamm. 2016;3:e276.spa
dc.relation.referencesBar-Or A, Steinman L, Behne J, Benitez-Ribas D, Chin P, Clare-Salzler M, et al. Restoring immune tolerance in neuromyelitis optica: part II. Neurol Neuroimmunol Neuroinflamm. 2016;3:e277spa
dc.rightsAndrea Catalina Nassar Tobón - 2021spa
dc.rights.accessrightsinfo:eu-repo/semantics/openAccessspa
dc.rights.coarhttp://purl.org/coar/access_right/c_abf2spa
dc.rights.urihttps://creativecommons.org/licenses/by-nc-sa/4.0/spa
dc.sourcehttps://revistas.juanncorpas.edu.co/index.php/cuarzo/article/view/521spa
dc.subjectLongitudinally extensive optic neuritiseng
dc.subjectlongitudinally extensive cervical myelopathyeng
dc.subjectoptic neuromyelitis spectrumeng
dc.subjectneuritis óptica bilateralspa
dc.subjectmielopatía cervical longitudinalmente extensaspa
dc.subjectespectro de neuromielitis ópticaspa
dc.titleMujer con diagnóstico de novo de espectro de neuromielitis óptica con anticuerpos para AQP4 positivo. Un Reporte de Casospa
dc.title.translatedWoman with a novo diagnosis of optic neuromyelitis spectrum with antibodies to AQP4 positive. A Case Report.eng
dc.typeArtículo de revistaspa
dc.type.coarhttp://purl.org/coar/resource_type/c_6501spa
dc.type.coarversionhttp://purl.org/coar/version/c_970fb48d4fbd8a85spa
dc.type.contentTextspa
dc.type.driverinfo:eu-repo/semantics/articlespa
dc.type.localJournal articleeng
dc.type.redcolhttp://purl.org/redcol/resource_type/ARTREFspa
dc.type.versioninfo:eu-repo/semantics/publishedVersionspa
dspace.entity.typePublicationspa

Archivos